NYSE · LABORATORY ANALYTICAL INSTRUMENTS · LARGE CAP
Bio-Rad Laboratories, Inc. BIO
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.6B
▲ 0.7% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
10.8%
Net margin · FY25
29.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.6B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
29 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
10.8%
Return on equity, FY2025
ROE
Operating margin1.8%
Net margin29.4%
Return on assets7.6%
Each USD of equity produced 11 cents of profit this year.
Returned to shareholders
USD 295.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 295.5M
Share of profit38.9%
Consecutive raises—
USD 295.5M in buybacks — 39% of the year's profit went back to shareholders.
Growth
+0.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.7%
+0.3%
+2.5%
+2.0%
Net income
−27.6%
+21.4%
+9.9%
EPS, diluted
−26.1%
+22.3%
+10.1%
Returned to shareholders
+11.7%
+26.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 10.6B
total assets, end of FY2025
Total assetsUSD 10.6B
EquityUSD 7.5B
CashUSD 529.8M
Gross debtUSD 1.2B
Net debtUSD 671.9M
Current ratio5.62×
Net debt stands at 9% of equity.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
2.6
2.6
2.7
2.8
2.9
2.5
2.3
2.3
2.2
2.1
2.0
2.2
2.1
2.1
2.1
1.9
1.8
1.8
Operating income $B
0.0
0.3
0.3
0.5
0.5
0.4
0.2
−0.1
0.1
0.1
0.2
0.1
0.2
0.3
0.3
0.3
0.2
0.2
EBITDA $B
0.2
0.4
0.5
0.6
0.6
0.6
0.4
0.0
0.3
0.2
0.3
0.3
0.3
0.4
0.4
0.4
0.3
·
Income tax $B
0.2
−0.5
−0.2
−1.1
1.2
1.1
0.5
0.1
−0.0
0.0
0.0
0.0
0.0
0.1
0.1
0.0
0.0
0.0
Net income $B
0.8
−1.8
−0.6
−3.6
4.3
3.8
1.8
0.4
0.1
0.0
0.1
0.1
0.1
0.2
0.2
0.2
0.1
0.1
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
10.8
−24.1
−6.9
−31.1
36.1
48.8
36.0
10.5
4.4
1.0
4.7
4.1
3.7
8.8
10.9
13.3
11.5
·
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
70 of 70
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed